Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 7

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 7
---

     - 
     
     -  
     414,744 
  
    Net
    loss 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     - 
     
     (4,227,967) 
     (4,227,967)
  
    Balance
    at September 30, 2024 (Successor) 
     3,125  
    $1,972,727  
     486  
    $360,000  
     2,853  
    $1,249,999  
     -  
    $-  
     73,771  
    $7  
    $66,378,194  
    $(2,073,607)
     
    $(71,589,745) 
    $(3,702,425)

    Convertible Preferred Stock  

    Additional  
       
    Total 

    Series Seed  
    Series A  
    Common Stock  
    Paid-in  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Deficit  
    Deficit 
  
    Balance at December 31, 2023 (Predecessor) 
     5,155,703  
    $4,077,560  
     22,764,764  
    $38,023,784  
     292  
    $-  
    $1,032,126  
    $(43,089,821) 
    $(42,057,695)
  
    Stock based compensation expense 
     -  
     -  
     -  
     -  
     -  
     -  
     4,431  
     -  
     4,431 
  
    Net loss 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     (572,211) 
     (572,211)